株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

感染症向け分子診断検査:世界市場シェア、戦略、将来予測

Molecular Diagnostics for Infectious Disease. Markets, Strategies and Trends. Volume & Price Forecasts by Pathogen and by Country. With Multiplex and Point of Care Market Analysis, Executive Guides and Customization. 2019 to 2023 - Global Version

発行 Howe Sound Research 商品コード 355181
出版日 ページ情報 英文 311 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.53円で換算しております。
Back to Top
感染症向け分子診断検査:世界市場シェア、戦略、将来予測 Molecular Diagnostics for Infectious Disease. Markets, Strategies and Trends. Volume & Price Forecasts by Pathogen and by Country. With Multiplex and Point of Care Market Analysis, Executive Guides and Customization. 2019 to 2023 - Global Version
出版日: 2018年03月14日 ページ情報: 英文 311 Pages
概要

当レポートでは、世界の感染症向け分子診断 (MD) の市場について分析し、、感染症の概要や発症件数、産業構造、主要企業のプロファイル、市場の促進・抑制要因や最新情勢、世界・各地域・主要国の市場動向見通しなどについて調査しております。

第1章 イントロダクションおよび市場定義

第2章 感染症:疾患別の市場分析

  • HIV (ヒト免疫不全ウイルス) (AIDS)
    • ウイルスの特性
    • 診断
    • 検査方法
    • 市場機会の分析
  • B型肝炎 (HBV)
  • C型肝炎 (HCV)
  • ヒトパピローマウイルス (HPV)
  • インフルエンザ
  • CTGC (クラミジア/淋病)
  • 結核
  • MRSA (メチシリン耐性黄色ブドウ球菌)
  • VRE (バンコマイシン耐性腸球菌)
  • 血液スクリーニング

第3章 産業概要

  • 参入企業
    • サプライヤー/製薬企業
    • 独立系・専門試験所
    • 独立系・総合試験所
    • 独立系・分析試験所
    • 公立試験所
    • 病院
    • 開業医
    • 保健所
  • 臨床試験所市場の内訳
    • 従来型の市場区分法
    • 試験所の注力分野とその内訳
  • 産業構造
    • 病院検査のシェア
    • 規模の経済性:病院 vs 大型試験所
    • 開業医向け試験所
    • 開業医とPOCT (ポイントオブケア検査)
  • 主な分子診断 (MD) 企業のプロファイル
  • 主要企業の市場シェア

第4章 市場動向

  • 市場成長の促進要因
  • 市場成長の抑制要因
  • 医療機器の自動化
  • 診断技術の開発

第5章 感染症向け分子診断市場:近年の主な動向

第6章 各国の市場規模:北米

  • 米国
  • カナダ

第7章 各国の市場規模:欧州

  • フランス
  • ドイツ
  • 英国
  • スペイン
  • イタリア
  • スイス
  • チェコ
  • ベルギー
  • ロシア
  • 他の欧州・旧ソ連諸国

第8章 各国の市場規模:アジア太平洋地域

  • 中国
  • 日本
  • 韓国
  • インド
  • オーストラリア
  • 他のアジア太平洋地域諸国

第9章 各国の市場規模:ラテンアメリカ・アフリカ・中東

  • ブラジル
  • メキシコ
  • 他のラテンアメリカ諸国
  • アフリカ・中東

第10章 世界市場の概略

  • 世界市場
    • HIV:市場規模・価格・収益額
    • B型肝炎:市場規模・価格・収益額
    • C型肝炎:市場規模・価格・収益額
    • ヒトパピローマウイルス:市場規模・価格・収益額
    • インフルエンザ:市場規模・価格・収益額
    • CHGC:市場規模・価格・収益額
    • 結核:市場規模・価格・収益額
    • MRSA:市場規模・価格・収益額
    • VRE:市場規模・価格・収益額
    • 血液検査・その他:市場規模・価格・収益額

付録

目次

Improvements in speed and accuracy drive demand for molecular diagnostic tests for infectious disease. Genetics advances create need for new diagnostics creating a fast moving market driven by technical change.

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing. In spite of the steady decline of disease prevalence, the diagnostic sector keeps growing. Find out why in the informative report.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report from Howe Sound Research. A range of dynamic trends are pushing market growth and company valuations. Trends like ......

  • changing demographics
  • emerging economies and global prosperity
  • biotechnology advances in genetics
  • pathogen evolution
  • climate change
  • globalization
  • the rise of rapid testing

Exciting technical developments especially in the seesaw between sequencing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

The report has hundreds of pages of information including a complete list of Current 2016 United States Medicare Fee Payment Schedules to help sharpen your pricing. Again, assistance in using the information is normally provided without additional charges. thi

The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

Table of Contents

1. Introduction and Market Definition

  • 1.1 What is Molecular Diagnostics
  • 1.2 The Diagnostics Revolution
  • 1.3 Market Definition
    • 1.3.1 Volumes
    • 1.3.2 Prices
    • 1.3.3 Revenue Market Size
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
    • 1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. The Infectious Diseases - Market Analysis by Disease

  • 2.1 HIV - Human Immunodeficiency Virus (AIDS)
    • 2.1.1 Virology
      • 2.1.1.1 Classification
      • 2.1.1.2 Structure and genome
      • 2.1.1.3 Tropism
      • 2.1.1.4 Replication cycle
      • 2.1.1.5 Genetic variability
    • 2.1.2 Diagnosis
    • 2.1.3 Testing
      • 2.1.3.1 Antibody tests
      • 2.1.3.2 Point of Care Tests (POCT)
      • 2.1.3.4 Antigen Tests
      • 2.1.3.5 Nucleic acid-based tests (NAT)
      • 2.1.3.6 Other tests used in HIV treatment
    • 2.1.4 Market Opportunity Analysis
  • 2.2 HBV - Hepatitis B
    • 2.2.1 Virology
      • 2.2.1.1 Genome
      • 2.2.1.2 Pathogenesis
      • 2.2.1.3 Hepatitis B virus replication
      • 2.2.1.4 Serotypes and genotypes
    • 2.2.2 Mechanisms
    • 2.2.3 Diagnosis
    • 2.2.4 Market Opportunity Analysis
  • 2.3 HCV - Hepatitis C
    • 2.3.1 Taxonomy
    • 2.3.2 Structure
      • 2.3.2.2 Genome
    • 2.3.3 Molecular biology
    • 2.3.4 Replication
    • 2.3.5 Genotypes
      • 2.3.5.1 Clinical importance
    • 2.3.6 Market Opportunity Analysis
  • 2.4 HPV - Human papillomavirus
    • 2.4.1 Virology
      • 2.4.1.1 E6/E7 proteins
      • 2.4.1.2 Role in cancer
      • 2.4.1.3 E2 research
      • 2.4.1.4 Latency period
      • 2.4.1.5 Clearance
    • 2.4.2 Diagnosis
      • 2.4.2.1 Cervical testing
      • 2.4.2.2 Oral testing
      • 2.4.2.3 Testing men
      • 2.4.2.4 Other testing
    • 2.4.3 Market Opportunity Analysis
  • 2.5 Influenza
    • 2.5.1 Virology
      • 2.5.1.1 Types of virus
      • 2.5.1.2 Influenzavirus A
      • 2.5.1.3 Influenzavirus B
      • 2.5.1.4 Influenzavirus C
      • 2.5.1.5 Structure, properties, and subtype nomenclature
      • 2.5.1.6 Replication
    • 2.5.2 Testing
      • 2.5.2.1 Advantages/Disadvantages of Molecular Assays
    • 2.5.3 Market Opportunity Analysis
  • 2.6 CTGC - Chlamydia/Gonorhea
    • 2.6.1 Gonorrhea
      • 2.6.1.1 Diagnosis
      • 2.6.1.2 Screening
    • 2.6.2 Chlamydia
      • 2.6.2.1 Diagnosis
      • 2.6.2.2 Screening
    • 2.6.3 Testing
      • 2.6.3.1 Nucleic acid amplification tests (NAATs).
      • 2.6.3.2 Performance of NAAT Tests
    • 2.6.4 Market Opportunity Analysis
  • 2.7 Tuberculosis
    • 2.7.1 Mycobacteria
    • 2.7.2 Diagnosis
      • 2.7.2.1 Active tuberculosis
      • 2.7.2.2 Latent tuberculosis
    • 2.7.3 Epidemiology
    • 2.7.4 Molecular Diagnostic Tests
    • 2.7.5 Market Opportunity Analysis
  • 2.8 MRSA - Methicillin-resistant Staphylococcus aureus
    • 2.8.1 Diagnosis
    • 2.8.2 FDA Approved Molecular Tests
    • 2.8.3 Market Opportunity Analysis
  • 2.9 VRE - Vancomycin-resistant Enterococcus
    • 2.9.1 FDA Approved MDx Tests for VRE
    • 2.9.2 Market Opportunity Analysis
  • 2.10 Blood Screening
    • 2.10.1 Collection and Testing
    • 2.10.2 FDA Approved Multiplex Assays
    • 2.10.3 Market Opportunity Analysis

3. Industry Overview

  • 3.1 Industry Participants
    • 3.1.1 Supplier/pharmaceutical
    • 3.1.2 Independent lab specialized/esoteric
    • 3.1.3 Independent lab national/regional
    • 3.1.4 Independent lab analytical
    • 3.1.5 Public National/regional lab
    • 3.1.6 Hospital lab
    • 3.1.7 Physician lab
    • 3.1.8 Audit body
  • 3.2 The Clinical Laboratory Market Segments
    • 3.2.1 Traditional Market Segmentation
    • 3.2.2 Laboratory Focus and Segmentation
  • 3.3 Industry Structure
    • 3.3.1 Hospital Testing Share
    • 3.3.2 Economies of Scale
    • 3.3.2.1 Hospital vs. Central Lab
    • 3.3.3 Physician Office Lab's
    • 3.3.4 Physician's and POCT
  • 3.4 Profiles of Key MDx Companies
    • 3.4.1 Abbott Diagnostics
    • 3.4.2 Alere (Abbott)
    • 3.4.3 BD Diagnostics
    • 3.4.4 Beckman Coulter
    • 3.4.5 bioMérieux
    • 3.4.6 Bio-Rad Laboratories
    • 3.4.7 Cepheid
    • 3.4.8 DiaSorin
    • 3.4.9 Eiken Chemical
    • 3.4.10 Grifols
    • 3.4.11 Hologic
    • 3.4.12 Illumina
    • 3.4.13 Janssen Diagnostics
    • 3.4.14 Luminex
    • 3.4.15 Meridian Bioscience
    • 3.4.16 Qiagen
    • 3.4.17 Quidel
    • 3.4.18 Roche Molecular Diagnostics
    • 3.4.19 Siemens Healthineers
    • 3.4.20 Thermo Fisher

4. Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 New Genotypes Creating New Markets
    • 4.1.2 Aging Population a Boon for All Diagnostics
    • 4.1.3 Developing World Driving ID Dx Growth.
    • 4.1.4 Point of Care - Why Centralization is Losing Steam
    • 4.1.5 Self Testing
    • 4.1.6 The Need for Speed
  • 4.2 Factors Limiting Growth
    • 4.2.1 Lower Costs
    • 4.2.2 Infectious Disease is Declining.
    • 4.2.3 Wellness Hurts.
    • 4.2.4 Economic Growth improves Living Standards
  • 4.3 Instrumentation and Automation
    • 4.3.1 Instruments Key to Market Share
    • 4.3.2 The Shrinking Machine.
    • 4.3.2 Multiplex, Point of Care and The Speed Factor.
  • 4.4 Diagnostic Technology Development
    • 4.4.1 The Sepsis Testing Market - A New Direction?
    • 4.4.2 POCT/Self Testing as a Disruptive Force
    • 4.4.3 The Genetics Play - One Test for All Known Infections
    • 4.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics

5. Molecular Dx - Infectious Disease Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
  • 5.3 QIAGEN enters into agreement to acquire STAT-Dx
  • 5.4 Curetis subsidiary Ares Genetics wins incubator stay in Silicon Valley
  • 5.5 Quidel Receives FDA Clearance for Its Point-of-Care Sofia® Lyme Fluorescent Immunoassay
  • 5.6 'Origami' diagnostics breakthrough set to benefit developing-world farmers
  • 5.7 NYU researchers adapt HIV test to Zika virus
  • 5.8 GA-EMS receives diagnostic device contract
  • 5.9 Biocartis & Immunexpress Sign Partnership for Sepsis
  • 5.10 PerkinElmer to Acquire Euroimmun for $1.3B
  • 5.11 Alveo Closes Financing to Create Accessible Diagnostics Devices
  • 5.12 Siemens Healthineers completes takeover of Fast Track Diagnostics
  • 5.13 Sekisui Diagnostics Enters Strategic Alliance with Mesa Biotech Inc
  • 5.14 Chembio and FIND to Develop Point-of-Care Multiplex Test
  • 5.15 Locus Biosciences and IDbyDNA Partner to Develop Companion Diagnostic Test .
  • 5.16 Alere bags FDA nod for rapid flu diagnostic
  • 5.17 FDA approves tests of tick-borne disease to protect blood supply
  • 5.18 Qiagen Trichomonas Assay Gets CE Mark
  • 5.19 Vela Diagnostics HSV Test Gets FDA Clearance

6. Country Market Sizes - North America

  • 6.1 United States of America
    • 6.1.1 HIV - Volumes, Prices, Revenues
    • 6.1.2 HBV - Volumes, Prices, Revenues
    • 6.1.3 HCV - Volumes, Prices, Revenues
    • 6.1.4 HPV - Volumes, Prices, Revenues
    • 6.1.5 FLU - Volumes, Prices, Revenues
    • 6.1.6 CHGC - Volumes, Prices, Revenues
    • 6.1.7 Tb - Volumes, Prices, Revenues
    • 6.1.8 MRSA - Volumes, Prices, Revenues
    • 6.1.9 VRE - Volumes, Prices, Revenues
    • 6.1.10 Screening/Other - Volumes, Prices, Revenues
  • 6.2 Canada
    • 6.2.1 HIV - Volumes, Prices, Revenues
    • 6.2.2 HBV - Volumes, Prices, Revenues
    • 6.2.3 HCV - Volumes, Prices, Revenues
    • 6.2.4 HPV - Volumes, Prices, Revenues
    • 6.2.5 FLU - Volumes, Prices, Revenues
    • 6.2.6 CHGC - Volumes, Prices, Revenues
    • 6.2.7 Tb - Volumes, Prices, Revenues
    • 6.2.8 MRSA - Volumes, Prices, Revenues
    • 6.2.9 VRE - Volumes, Prices, Revenues
    • 6.2.10 Screening/Other - Volumes, Prices, Revenues

7. Country Markets - Europe

  • 7.1 France
    • 7.1.1 HIV - Volumes, Prices, Revenues
    • 7.1.2 HBV - Volumes, Prices, Revenues
    • 7.1.3 HCV - Volumes, Prices, Revenues
    • 7.1.4 HPV - Volumes, Prices, Revenues
    • 7.1.5 FLU - Volumes, Prices, Revenues
    • 7.1.6 CHGC - Volumes, Prices, Revenues
    • 7.1.7 Tb - Volumes, Prices, Revenues
    • 7.1.8 MRSA - Volumes, Prices, Revenues
    • 7.1.9 VRE - Volumes, Prices, Revenues
    • 7.1.10 Screening/Other - Volumes, Prices, Revenues
  • 7.2 Germany
    • 7.2.1 HIV - Volumes, Prices, Revenues
    • 7.2.2 HBV - Volumes, Prices, Revenues
    • 7.2.3 HCV - Volumes, Prices, Revenues
    • 7.2.4 HPV - Volumes, Prices, Revenues
    • 7.2.5 FLU - Volumes, Prices, Revenues
    • 7.2.6 CHGC - Volumes, Prices, Revenues
    • 7.2.7 Tb - Volumes, Prices, Revenues
    • 7.2.8 MRSA - Volumes, Prices, Revenues
    • 7.2.9 VRE - Volumes, Prices, Revenues
    • 7.2.10 Screening/Other - Volumes, Prices, Revenues
  • 7.3 United Kingdom
    • 7.3.1 HIV - Volumes, Prices, Revenues
    • 7.3.2 HBV - Volumes, Prices, Revenues
    • 7.3.3 HCV - Volumes, Prices, Revenues
    • 7.3.4 HPV - Volumes, Prices, Revenues
    • 7.3.5 FLU - Volumes, Prices, Revenues
    • 7.3.6 CHGC - Volumes, Prices, Revenues
    • 7.3.7 Tb - Volumes, Prices, Revenues
    • 7.3.8 MRSA - Volumes, Prices, Revenues
    • 7.3.9 VRE - Volumes, Prices, Revenues
    • 7.3.10 Screening/Other - Volumes, Prices, Revenues
  • 7.4 Spain
    • 7.4.1 HIV - Volumes, Prices, Revenues
    • 7.4.2 HBV - Volumes, Prices, Revenues
    • 7.4.3 HCV - Volumes, Prices, Revenues
    • 7.4.4 HPV - Volumes, Prices, Revenues
    • 7.4.5 FLU - Volumes, Prices, Revenues
    • 7.4.6 CHGC - Volumes, Prices, Revenues
    • 7.4.7 Tb - Volumes, Prices, Revenues
    • 7.4.8 MRSA - Volumes, Prices, Revenues
    • 7.4.9 VRE - Volumes, Prices, Revenues
    • 7.4.10 Screening/Other - Volumes, Prices, Revenues
  • 7.5 Italy
    • 7.5.1 HIV - Volumes, Prices, Revenues
    • 7.5.2 HBV - Volumes, Prices, Revenues
    • 7.5.3 HCV - Volumes, Prices, Revenues
    • 7.5.4 HPV - Volumes, Prices, Revenues
    • 7.5.5 FLU - Volumes, Prices, Revenues
    • 7.5.6 CHGC - Volumes, Prices, Revenues
    • 7.5.7 Tb - Volumes, Prices, Revenues
    • 7.5.8 MRSA - Volumes, Prices, Revenues
    • 7.5.9 VRE - Volumes, Prices, Revenues
    • 7.5.10 Screening/Other - Volumes, Prices, Revenues
  • 7.6 Switzerland
    • 7.6.1 HIV - Volumes, Prices, Revenues
    • 7.6.2 HBV - Volumes, Prices, Revenues
    • 7.6.3 HCV - Volumes, Prices, Revenues
    • 7.6.4 HPV - Volumes, Prices, Revenues
    • 7.6.5 FLU - Volumes, Prices, Revenues
    • 7.6.6 CHGC - Volumes, Prices, Revenues
    • 7.6.7 Tb - Volumes, Prices, Revenues
    • 7.6.8 MRSA - Volumes, Prices, Revenues
    • 7.6.9 VRE - Volumes, Prices, Revenues
    • 7.6.10 Screening/Other - Volumes, Prices, Revenues
  • 7.7 Czech Republic
    • 7.7.1 HIV - Volumes, Prices, Revenues
    • 7.7.2 HBV - Volumes, Prices, Revenues
    • 7.7.3 HCV - Volumes, Prices, Revenues
    • 7.7.4 HPV - Volumes, Prices, Revenues
    • 7.7.5 FLU - Volumes, Prices, Revenues
    • 7.7.6 CHGC - Volumes, Prices, Revenues
    • 7.7.7 Tb - Volumes, Prices, Revenues
    • 7.7.8 MRSA - Volumes, Prices, Revenues
    • 7.7.9 VRE - Volumes, Prices, Revenues
    • 7.7.10 Screening/Other - Volumes, Prices, Revenues
  • 7.8 Belgium
    • 7.8.1 HIV - Volumes, Prices, Revenues
    • 7.8.2 HBV - Volumes, Prices, Revenues
    • 7.8.3 HCV - Volumes, Prices, Revenues
    • 7.8.4 HPV - Volumes, Prices, Revenues
    • 7.8.5 FLU - Volumes, Prices, Revenues
    • 7.8.6 CHGC - Volumes, Prices, Revenues
    • 7.8.7 Tb - Volumes, Prices, Revenues
    • 7.8.8 MRSA - Volumes, Prices, Revenues
    • 7.8.9 VRE - Volumes, Prices, Revenues
    • 7.8.10 Screening/Other - Volumes, Prices, Revenues
  • 7.9 Russia
    • 7.9.1 HIV - Volumes, Prices, Revenues
    • 7.9.2 HBV - Volumes, Prices, Revenues
    • 7.9.3 HCV - Volumes, Prices, Revenues
    • 7.9.4 HPV - Volumes, Prices, Revenues
    • 7.9.5 FLU - Volumes, Prices, Revenues
    • 7.9.6 CHGC - Volumes, Prices, Revenues
    • 7.9.7 Tb - Volumes, Prices, Revenues
    • 7.9.8 MRSA - Volumes, Prices, Revenues
    • 7.9.9 VRE - Volumes, Prices, Revenues
    • 7.9.10 Screening/Other - Volumes, Prices, Revenues
  • 7.10 Remainder of Europe and Former Soviet Union
    • 7.10.1 HIV - Volumes, Prices, Revenues
    • 7.10.2 HBV - Volumes, Prices, Revenues
    • 7.10.3 HCV - Volumes, Prices, Revenues
    • 7.10.4 HPV - Volumes, Prices, Revenues
    • 7.10.5 FLU - Volumes, Prices, Revenues
    • 7.10.6 CHGC - Volumes, Prices, Revenues
    • 7.10.7 Tb - Volumes, Prices, Revenues
    • 7.10.8 MRSA - Volumes, Prices, Revenues
    • 7.10.9 VRE - Volumes, Prices, Revenues
    • 7.10.10 Screening/Other - Volumes, Prices, Revenues

8. Country Markets - Asia Pacific

  • 8.1 China
    • 8.1.1 HIV - Volumes, Prices, Revenues
    • 8.1.2 HBV - Volumes, Prices, Revenues
    • 8.1.3 HCV - Volumes, Prices, Revenues
    • 8.1.4 HPV - Volumes, Prices, Revenues
    • 8.1.5 FLU - Volumes, Prices, Revenues
    • 8.1.6 CHGC - Volumes, Prices, Revenues
    • 8.1.7 Tb - Volumes, Prices, Revenues
    • 8.1.8 MRSA - Volumes, Prices, Revenues
    • 8.1.9 VRE - Volumes, Prices, Revenues
    • 8.1.10 Screening/Other - Volumes, Prices, Revenues
  • 8.2 Japan
    • 8.2.1 HIV - Volumes, Prices, Revenues
    • 8.2.2 HBV - Volumes, Prices, Revenues
    • 8.2.3 HCV - Volumes, Prices, Revenues
    • 8.2.4 HPV - Volumes, Prices, Revenues
    • 8.2.5 FLU - Volumes, Prices, Revenues
    • 8.2.6 CHGC - Volumes, Prices, Revenues
    • 8.2.7 Tb - Volumes, Prices, Revenues
    • 8.2.8 MRSA - Volumes, Prices, Revenues
    • 8.2.9 VRE - Volumes, Prices, Revenues
    • 8.2.10 Screening/Other - Volumes, Prices, Revenues
  • 8.3 South Korea
    • 8.3.1 HIV - Volumes, Prices, Revenues
    • 8.3.2 HBV - Volumes, Prices, Revenues
    • 8.3.3 HCV - Volumes, Prices, Revenues
    • 8.3.4 HPV - Volumes, Prices, Revenues
    • 8.3.5 FLU - Volumes, Prices, Revenues
    • 8.3.6 CHGC - Volumes, Prices, Revenues
    • 8.3.7 Tb - Volumes, Prices, Revenues
    • 8.3.8 MRSA - Volumes, Prices, Revenues
    • 8.3.9 VRE - Volumes, Prices, Revenues
    • 8.3.10 Screening/Other - Volumes, Prices, Revenues
  • 8.4 India
    • 8.4.1 HIV - Volumes, Prices, Revenues
    • 8.4.2 HBV - Volumes, Prices, Revenues
    • 8.4.3 HCV - Volumes, Prices, Revenues
    • 8.4.4 HPV - Volumes, Prices, Revenues
    • 8.4.5 FLU - Volumes, Prices, Revenues
    • 8.4.6 CHGC - Volumes, Prices, Revenues
    • 8.4.7 Tb - Volumes, Prices, Revenues
    • 8.4.8 MRSA - Volumes, Prices, Revenues
    • 8.4.9 VRE - Volumes, Prices, Revenues
    • 8.4.10 Screening/Other - Volumes, Prices, Revenues
  • 8.5 Australia
    • 8.5.1 HIV - Volumes, Prices, Revenues
    • 8.5.2 HBV - Volumes, Prices, Revenues
    • 8.5.3 HCV - Volumes, Prices, Revenues
    • 8.5.4 HPV - Volumes, Prices, Revenues
    • 8.5.5 FLU - Volumes, Prices, Revenues
    • 8.5.6 CHGC - Volumes, Prices, Revenues
    • 8.5.7 Tb - Volumes, Prices, Revenues
    • 8.5.8 MRSA - Volumes, Prices, Revenues
    • 8.5.9 VRE - Volumes, Prices, Revenues
    • 8.5.10 Screening/Other - Volumes, Prices, Revenues
  • 8.6 Rest of Asia Pacific
    • 8.6.1 HIV - Volumes, Prices, Revenues
    • 8.6.2 HBV - Volumes, Prices, Revenues
    • 8.6.3 HCV - Volumes, Prices, Revenues
    • 8.6.4 HPV - Volumes, Prices, Revenues
    • 8.6.5 FLU - Volumes, Prices, Revenues
    • 8.6.6 CHGC - Volumes, Prices, Revenues
    • 8.6.7 Tb - Volumes, Prices, Revenues
    • 8.6.8 MRSA - Volumes, Prices, Revenues
    • 8.6.9 VRE - Volumes, Prices, Revenues
    • 8.6.10 Screening/Other - Volumes, Prices, Revenues

9. Country Markets - Latin America, Africa & The Middle East

  • 9.1 Brazil
    • 9.1.1 HIV - Volumes, Prices, Revenues
    • 9.1.2 HBV - Volumes, Prices, Revenues
    • 9.1.3 HCV - Volumes, Prices, Revenues
    • 9.1.4 HPV - Volumes, Prices, Revenues
    • 9.1.5 FLU - Volumes, Prices, Revenues
    • 9.1.6 CHGC - Volumes, Prices, Revenues
    • 9.1.7 Tb - Volumes, Prices, Revenues
    • 9.1.8 MRSA - Volumes, Prices, Revenues
    • 9.1.9 VRE - Volumes, Prices, Revenues
    • 9.1.10 Screening/Other - Volumes, Prices, Revenues
  • 9.2 Mexico
    • 9.2.1 HIV - Volumes, Prices, Revenues
    • 9.2.2 HBV - Volumes, Prices, Revenues
    • 9.2.3 HCV - Volumes, Prices, Revenues
    • 9.2.4 HPV - Volumes, Prices, Revenues
    • 9.2.5 FLU - Volumes, Prices, Revenues
    • 9.2.6 CHGC - Volumes, Prices, Revenues
    • 9.2.7 Tb - Volumes, Prices, Revenues
    • 9.2.8 MRSA - Volumes, Prices, Revenues
    • 9.2.9 VRE - Volumes, Prices, Revenues
    • 9.2.10 Screening/Other - Volumes, Prices, Revenues
  • 9.3 Remainder of Latin America
    • 9.3.1 HIV - Volumes, Prices, Revenues
    • 9.3.2 HBV - Volumes, Prices, Revenues
    • 9.3.3 HCV - Volumes, Prices, Revenues
    • 9.3.4 HPV - Volumes, Prices, Revenues
    • 9.3.5 FLU - Volumes, Prices, Revenues
    • 9.3.6 CHGC - Volumes, Prices, Revenues
    • 9.3.7 Tb - Volumes, Prices, Revenues
    • 9.3.8 MRSA - Volumes, Prices, Revenues
    • 9.3.9 VRE - Volumes, Prices, Revenues
    • 9.3.10 Screening/Other - Volumes, Prices, Revenues
  • 9.4 Africa & The Middle East
    • 9.4.1 HIV - Volumes, Prices, Revenues
    • 9.4.2 HBV - Volumes, Prices, Revenues
    • 9.4.3 HCV - Volumes, Prices, Revenues
    • 9.4.4 HPV - Volumes, Prices, Revenues
    • 9.4.5 FLU - Volumes, Prices, Revenues
    • 9.4.6 CHGC - Volumes, Prices, Revenues
    • 9.4.7 Tb - Volumes, Prices, Revenues
    • 9.4.8 MRSA - Volumes, Prices, Revenues
    • 9.4.9 VRE - Volumes, Prices, Revenues
    • 9.4.10 Screening/Other - Volumes, Prices, Revenues

10. Global Market Summary

  • 10.1 Global Market
    • 10.1.1 HIV - Volumes, Prices, Revenues
    • 10.1.2 HBV - Volumes, Prices, Revenues
    • 10.1.3 HCV - Volumes, Prices, Revenues
    • 10.1.4 HPV - Volumes, Prices, Revenues
    • 10.1.5 FLU - Volumes, Prices, Revenues
    • 10.1.6 CHGC - Volumes, Prices, Revenues
    • 10.1.7 Tb - Volumes, Prices, Revenues
    • 10.1.8 MRSA - Volumes, Prices, Revenues
    • 10.1.9 VRE - Volumes, Prices, Revenues
    • 10.1.10 Screening/Other - Volumes, Prices, Revenues

Appendices

  • I. United States Medicare System: January 2016 Clinical Laboratory Fees Schedule - National Limit and Midpoint
  • II. FDA Approved Human Genetic Tests
  • III. FDA Approved Microbial Tests
  • III. FDA Approved Pharmacogenomics Tests

Table of Tables

  • Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
  • Table 2 Classification of HIV Species
  • Table 3 HIV Tests - CMS Codes & Prices
  • Table 4 Current HIV Molecular Tests and Instruments Used
  • Table 5 HBV Tests - CMS Codes & Prices
  • Table 6 HCV Tests - CMS Codes & Prices
  • Table 7 HPV Clearance Rates
  • Table 8 HPV Tests - CMS Codes & Prices
  • Table 9 HPV Tests, Technology, Types
  • Table 10 Types of Influenza Tests
  • Table 11 Influenza Tests - CMS Codes & Prices
  • Table 12 FDA Cleared Molecular Assays for Influenza
  • Table 13 FDA Cleared NAAT CTGC Tests
  • Table 14 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 15 Influenza Tests - CMS Codes & Prices
  • Table 16 FDA Approved MDx Tests for Tuberculosis
  • Table 17 Tuberculosis Tests - CMS Codes & Prices
  • Table 18 FDA Approved Tests for MRSA
  • Table 19 MRSA Tests - CMS Codes & Prices
  • Table 20 FDA Approved Tests for VRE
  • Table 21 VRE Tests - CMS Codes & Prices
  • Table 22 FDA Approved Multiplex Assays
  • Table 23 Market Players by Type
  • Table 24 Clinical Laboratory Departments and Segments
  • Table 25 Laboratory Management Focus - Different Approaches
  • Table 26 Key Segmentation Variables Going Forward
  • Table 27 Five Factors Driving Growth
  • Table 28 Four Factors Limiting Growth
  • Table 29 Key Diagnostic Laboratory Technology Trends
  • Table 30 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 31 MDx HBV - Volume Price and Revenue Forecast
  • Table 32 HCV - Volume Price and Revenue Forecast
  • Table 33 HPV - Volume Price and Revenue Forecast
  • Table 34 FLU - Volume Price and Revenue Forecast
  • Table 35 CHGC - Volume Price and Revenue Forecast
  • Table 36 Tb - Volume Price and Revenue Forecast
  • Table 37 MRSA - Volume Price and Revenue Forecast
  • Table 38 VRE - Volume Price and Revenue Forecast
  • Table 39 Screening/Other - Volume Price and Revenue Forecast
  • Table 40 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 41 MDx HBV - Volume Price and Revenue Forecast
  • Table 42 HCV - Volume Price and Revenue Forecast
  • Table 43 HPV - Volume Price and Revenue Forecast
  • Table 44 FLU - Volume Price and Revenue Forecast
  • Table 45 CHGC - Volume Price and Revenue Forecast
  • Table 46 Tb - Volume Price and Revenue Forecast
  • Table 47 MRSA - Volume Price and Revenue Forecast
  • Table 48 VRE - Volume Price and Revenue Forecast
  • Table 49 Screening/Other - Volume Price and Revenue Forecast
  • Table 50 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 51 MDx HBV - Volume Price and Revenue Forecast
  • Table 52 HCV - Volume Price and Revenue Forecast
  • Table 53 HPV - Volume Price and Revenue Forecast
  • Table 54 FLU - Volume Price and Revenue Forecast
  • Table 55 CHGC - Volume Price and Revenue Forecast
  • Table 56 Tb - Volume Price and Revenue Forecast
  • Table 57 MRSA - Volume Price and Revenue Forecast
  • Table 58 VRE - Volume Price and Revenue Forecast
  • Table 59 Screening/Other - Volume Price and Revenue Forecast
  • Table 60 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 61 MDx HBV - Volume Price and Revenue Forecast
  • Table 62 HCV - Volume Price and Revenue Forecast
  • Table 63 HPV - Volume Price and Revenue Forecast
  • Table 64 FLU - Volume Price and Revenue Forecast
  • Table 65 CHGC - Volume Price and Revenue Forecast
  • Table 66 Tb - Volume Price and Revenue Forecast
  • Table 67 MRSA - Volume Price and Revenue Forecast
  • Table 68 VRE - Volume Price and Revenue Forecast
  • Table 69 Screening/Other - Volume Price and Revenue Forecast
  • Table 70 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 71 MDx HBV - Volume Price and Revenue Forecast
  • Table 72 HCV - Volume Price and Revenue Forecast
  • Table 73 HPV - Volume Price and Revenue Forecast
  • Table 74 FLU - Volume Price and Revenue Forecast
  • Table 75 CHGC - Volume Price and Revenue Forecast
  • Table 76 Tb - Volume Price and Revenue Forecast
  • Table 77 MRSA - Volume Price and Revenue Forecast
  • Table 78 VRE - Volume Price and Revenue Forecast
  • Table 79 Screening/Other - Volume Price and Revenue Forecast
  • Table 80 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 81 MDx HBV - Volume Price and Revenue Forecast
  • Table 82 HCV - Volume Price and Revenue Forecast
  • Table 83 HPV - Volume Price and Revenue Forecast
  • Table 84 FLU - Volume Price and Revenue Forecast
  • Table 85 CHGC - Volume Price and Revenue Forecast
  • Table 86 Tb - Volume Price and Revenue Forecast
  • Table 87 MRSA - Volume Price and Revenue Forecast
  • Table 88 VRE - Volume Price and Revenue Forecast
  • Table 89 Screening/Other - Volume Price and Revenue Forecast
  • Table 90 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 91 MDx HBV - Volume Price and Revenue Forecast
  • Table 92 HCV - Volume Price and Revenue Forecast
  • Table 93 HPV - Volume Price and Revenue Forecast
  • Table 94 FLU - Volume Price and Revenue Forecast
  • Table 95 CHGC - Volume Price and Revenue Forecast
  • Table 96 Tb - Volume Price and Revenue Forecast
  • Table 97 MRSA - Volume Price and Revenue Forecast
  • Table 98 VRE - Volume Price and Revenue Forecast
  • Table 99 Screening/Other - Volume Price and Revenue Forecast
  • Table 100 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 101 MDx HBV - Volume Price and Revenue Forecast
  • Table 102 HCV - Volume Price and Revenue Forecast
  • Table 103 HPV - Volume Price and Revenue Forecast
  • Table 104 FLU - Volume Price and Revenue Forecast
  • Table 105 CHGC - Volume Price and Revenue Forecast
  • Table 106 Tb - Volume Price and Revenue Forecast
  • Table 107 MRSA - Volume Price and Revenue Forecast
  • Table 108 VRE - Volume Price and Revenue Forecast
  • Table 109 Screening/Other - Volume Price and Revenue Forecast
  • Table 110 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 111 MDx HBV - Volume Price and Revenue Forecast
  • Table 112 HCV - Volume Price and Revenue Forecast
  • Table 113 HPV - Volume Price and Revenue Forecast
  • Table 114 FLU - Volume Price and Revenue Forecast
  • Table 115 CHGC - Volume Price and Revenue Forecast
  • Table 116 Tb - Volume Price and Revenue Forecast
  • Table 117 MRSA - Volume Price and Revenue Forecast
  • Table 118 VRE - Volume Price and Revenue Forecast
  • Table 119 Screening/Other - Volume Price and Revenue Forecast
  • Table 120 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 121 MDx HBV - Volume Price and Revenue Forecast
  • Table 122 HCV - Volume Price and Revenue Forecast
  • Table 123 HPV - Volume Price and Revenue Forecast
  • Table 124 FLU - Volume Price and Revenue Forecast
  • Table 125 CHGC - Volume Price and Revenue Forecast
  • Table 126 Tb - Volume Price and Revenue Forecast
  • Table 127 MRSA - Volume Price and Revenue Forecast
  • Table 128 VRE - Volume Price and Revenue Forecast
  • Table 129 Screening/Other - Volume Price and Revenue Forecast
  • Table 130 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 131 MDx HBV - Volume Price and Revenue Forecast
  • Table 132 HCV - Volume Price and Revenue Forecast
  • Table 133 HPV - Volume Price and Revenue Forecast
  • Table 134 FLU - Volume Price and Revenue Forecast
  • Table 135 CHGC - Volume Price and Revenue Forecast
  • Table 136 Tb - Volume Price and Revenue Forecast
  • Table 137 MRSA - Volume Price and Revenue Forecast
  • Table 138 VRE - Volume Price and Revenue Forecast
  • Table 139 Screening/Other - Volume Price and Revenue Forecast
  • Table 140 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 141 MDx HBV - Volume Price and Revenue Forecast
  • Table 142 HCV - Volume Price and Revenue Forecast
  • Table 143 HPV - Volume Price and Revenue Forecast
  • Table 144 FLU - Volume Price and Revenue Forecast
  • Table 145 CHGC - Volume Price and Revenue Forecast
  • Table 146 Tb - Volume Price and Revenue Forecast
  • Table 147 MRSA - Volume Price and Revenue Forecast
  • Table 148 VRE - Volume Price and Revenue Forecast
  • Table 149 Screening/Other - Volume Price and Revenue Forecast
  • Table 150 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 151 MDx HBV - Volume Price and Revenue Forecast
  • Table 152 HCV - Volume Price and Revenue Forecast
  • Table 153 HPV - Volume Price and Revenue Forecast
  • Table 154 FLU - Volume Price and Revenue Forecast
  • Table 155 CHGC - Volume Price and Revenue Forecast
  • Table 156 Tb - Volume Price and Revenue Forecast
  • Table 157 MRSA - Volume Price and Revenue Forecast
  • Table 158 VRE - Volume Price and Revenue Forecast
  • Table 159 Screening/Other - Volume Price and Revenue Forecast
  • Table 160 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 161 MDx HBV - Volume Price and Revenue Forecast
  • Table 162 HCV - Volume Price and Revenue Forecast
  • Table 163 HPV - Volume Price and Revenue Forecast
  • Table 164 FLU - Volume Price and Revenue Forecast
  • Table 165 CHGC - Volume Price and Revenue Forecast
  • Table 166 Tb - Volume Price and Revenue Forecast
  • Table 167 MRSA - Volume Price and Revenue Forecast
  • Table 168 VRE - Volume Price and Revenue Forecast
  • Table 169 Screening/Other - Volume Price and Revenue Forecast
  • Table 170 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 171 MDx HBV - Volume Price and Revenue Forecast
  • Table 172 HCV - Volume Price and Revenue Forecast
  • Table 173 HPV - Volume Price and Revenue Forecast
  • Table 174 FLU - Volume Price and Revenue Forecast
  • Table 175 CHGC - Volume Price and Revenue Forecast
  • Table 176 Tb - Volume Price and Revenue Forecast
  • Table 177 MRSA - Volume Price and Revenue Forecast
  • Table 178 VRE - Volume Price and Revenue Forecast
  • Table 179 Screening/Other - Volume Price and Revenue Forecast
  • Table 180 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 181 MDx HBV - Volume Price and Revenue Forecast
  • Table 182 HCV - Volume Price and Revenue Forecast
  • Table 183 HPV - Volume Price and Revenue Forecast
  • Table 184 FLU - Volume Price and Revenue Forecast
  • Table 185 CHGC - Volume Price and Revenue Forecast
  • Table 186 Tb - Volume Price and Revenue Forecast
  • Table 187 MRSA - Volume Price and Revenue Forecast
  • Table 188 VRE - Volume Price and Revenue Forecast
  • Table 189 Screening/Other - Volume Price and Revenue Forecast
  • Table 190 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 191 MDx HBV - Volume Price and Revenue Forecast
  • Table 192 HCV - Volume Price and Revenue Forecast
  • Table 193 HPV - Volume Price and Revenue Forecast
  • Table 194 FLU - Volume Price and Revenue Forecast
  • Table 195 CHGC - Volume Price and Revenue Forecast
  • Table 196 Tb - Volume Price and Revenue Forecast
  • Table 197 MRSA - Volume Price and Revenue Forecast
  • Table 198 VRE - Volume Price and Revenue Forecast
  • Table 199 Screening/Other - Volume Price and Revenue Forecast
  • Table 200 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 201 MDx HBV - Volume Price and Revenue Forecast
  • Table 202 HCV - Volume Price and Revenue Forecast
  • Table 203 HPV - Volume Price and Revenue Forecast
  • Table 204 FLU - Volume Price and Revenue Forecast
  • Table 205 CHGC - Volume Price and Revenue Forecast
  • Table 206 Tb - Volume Price and Revenue Forecast
  • Table 207 MRSA - Volume Price and Revenue Forecast
  • Table 208 VRE - Volume Price and Revenue Forecast
  • Table 209 Screening/Other - Volume Price and Revenue Forecast
  • Table 210 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 211 MDx HBV - Volume Price and Revenue Forecast
  • Table 212 HCV - Volume Price and Revenue Forecast
  • Table 213 HPV - Volume Price and Revenue Forecast
  • Table 214 FLU - Volume Price and Revenue Forecast
  • Table 215 CHGC - Volume Price and Revenue Forecast
  • Table 216 Tb - Volume Price and Revenue Forecast
  • Table 217 MRSA - Volume Price and Revenue Forecast
  • Table 218 VRE - Volume Price and Revenue Forecast
  • Table 219 Screening/Other - Volume Price and Revenue Forecast
  • Table 220 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 221 MDx HBV - Volume Price and Revenue Forecast
  • Table 222 HCV - Volume Price and Revenue Forecast
  • Table 223 HPV - Volume Price and Revenue Forecast
  • Table 224 FLU - Volume Price and Revenue Forecast
  • Table 225 CHGC - Volume Price and Revenue Forecast
  • Table 226 Tb - Volume Price and Revenue Forecast
  • Table 227 MRSA - Volume Price and Revenue Forecast
  • Table 228 VRE - Volume Price and Revenue Forecast
  • Table 229 Screening/Other - Volume Price and Revenue Forecast
  • Table 230 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 231 MDx HBV - Volume Price and Revenue Forecast
  • Table 232 HCV - Volume Price and Revenue Forecast
  • Table 233 HPV - Volume Price and Revenue Forecast
  • Table 234 FLU - Volume Price and Revenue Forecast
  • Table 235 CHGC - Volume Price and Revenue Forecast
  • Table 236 Tb - Volume Price and Revenue Forecast
  • Table 237 MRSA - Volume Price and Revenue Forecast
  • Table 238 VRE - Volume Price and Revenue Forecast
  • Table 239 Screening/Other - Volume Price and Revenue Forecast
  • Table 240 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 241 MDx HBV - Volume Price and Revenue Forecast
  • Table 242 HCV - Volume Price and Revenue Forecast
  • Table 243 HPV - Volume Price and Revenue Forecast
  • Table 244 FLU - Volume Price and Revenue Forecast
  • Table 245 CHGC - Volume Price and Revenue Forecast
  • Table 246 Tb - Volume Price and Revenue Forecast
  • Table 247 MRSA - Volume Price and Revenue Forecast
  • Table 248 VRE - Volume Price and Revenue Forecast
  • Table 249 Screening/Other - Volume Price and Revenue Forecast
  • Table 250 HIV Infectious Disease - Volume Price and Revenue Forecast
  • Table 251 MDx HBV - Volume Price and Revenue Forecast
  • Table 252 HCV - Volume Price and Revenue Forecast
  • Table 253 HPV - Volume Price and Revenue Forecast
  • Table 254 FLU - Volume Price and Revenue Forecast
  • Table 255 CHGC - Volume Price and Revenue Forecast
  • Table 256 Tb - Volume Price and Revenue Forecast
  • Table 257 MRSA - Volume Price and Revenue Forecast
  • Table 258 VRE - Volume Price and Revenue Forecast
  • Table 259 Screening/Other - Volume Price and Revenue Forecast
  • Table 260 2015 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 2 HIV Virion
  • Figure 3 Diagram of the HIV Replication Cycle
  • Figure 4 The Structure of the HBV Virus
  • Figure 5 Hepatitis B Replication
  • Figure 6 Structure of the HCV Virus
  • Figure 7 HCV Replication Cycle
  • Figure 8 Structure of the Influenza Virion
  • Figure 9 Influenza Replication
  • Figure 10 Scanning Electronmicrograph of Tuberculosis
  • Figure 11 Percentage of World Population Over 65
  • Figure 12 Chart Infectious Disease Decline
Back to Top